Understanding precisely how a drug activates its target receptor — not just whether it binds — is emerging as one of the most consequential questions in cardiovascular and fibrosis medicine. The relaxin receptor RXFP1 sits at the center of multiple mid-stage clinical trials, yet the structural logic governing how different therapeutic agents switch it on has remained unresolved. New structural data now clarifies this picture in ways that could meaningfully reshape next-generation drug design.
Using cryo-electron microscopy, investigators captured three distinct conformational states of RXFP1: the unoccupied receptor, the receptor bound to relaxin-2 (the body's native peptide agonist), and the receptor occupied by AZD5462, a small-molecule drug candidate currently in clinical development. The two agonists activate the receptor through fundamentally different architectural mechanisms. Relaxin-2 engages the extracellular ectodomain and drives a structural reorganization of an intervening linker region into a helical configuration — a process confirmed through hydrogen-deuterium exchange mass spectrometry. AZD5462, by contrast, bypasses the ectodomain entirely, lodging within the transmembrane bundle and locking the receptor into an active conformation that preferentially recruits β-arrestin rather than G proteins. Neither mechanism resembles the established "push-pull" activation logic seen in closely related glycoprotein hormone receptors.
This divergence carries real pharmacological weight. In GPCR pharmacology, biased agonism — the selective engagement of β-arrestin versus G protein pathways — is associated with distinct downstream signaling profiles and, potentially, distinct therapeutic and side-effect signatures. The fact that a small molecule can access a β-arrestin-biased active state through the transmembrane domain, while the native peptide operates via ectodomain engagement, opens a credible rationale for designing pathway-selective relaxin receptor modulators. Limitations apply: this is a preprint structural study, not a clinical outcomes paper, and functional bias in cell-based or animal models remains to be fully characterized. Still, for a receptor implicated in heart failure, pulmonary fibrosis, and systemic sclerosis, this structural framework is a meaningful advance rather than an incremental one.